Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | FDPS | P14324 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286382 | 1.00 | CA1 (0.52) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL8898661 | 0.93 | CA1 (0.61) | CA1FDPSACE2FFAR4 | |
| SCHEMBL13267645 | 0.91 | CA1 (0.59) | CA1FDPSACE2FFAR4 | |
| SCHEMBL26106191 | 0.91 | CA1 (0.59) | CA1FDPSACE2FFAR4 | |
| SCHEMBL486916 | 0.91 | CA1 (0.59) | CA1FDPSACE2FFAR4 | |
| SCHEMBL268557 | 0.84 | — | — | |
| SCHEMBL10890015 | 0.84 | — | — | |
| SCHEMBL3099302 | 0.83 | CA1 (0.50) | CA1FDPSMAPK1 | |
| SCHEMBL2526282 | 0.83 | CA1 (0.50) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL10904102 | 0.83 | CA1 (0.50) | CA1FDPSMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | CA1 2960/4885FDPS 1394/4885CA2 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.